PHARMACEUTICAL COMPOSITION CONTAINING AN ORALLY ACTIVE NMDA RECEPTOR ANTAGONIST IN AN ORAL DOSAGE FORM AND METHOD OF MAKING THE SAME

摘要

This invention relates to a pharmaceutical composition containing an orally active NMDA receptor antagonist preferentially indicated for the treatment of moderate to severe dementia of the alzheimer"s type in an oral dosage form and the method of making the same. The compound is memantine and preferentially in the form of salt of hydrochloride and chemically it is 1-amino-3,5-dimethyladamantane hydrochloride. The molecular formula is C12H21N" HCI and the molecular weight is 215.76. Memantine HCI occurs as a fine white to off-white powder and is soluble in water.